RATIONALE: Smoking rates are up to five times higher in people with schizophrenia than in the general population, placing these individuals at high risk for smoking-related health problems. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, is a promising aid for smoking cessation in this population. To maximize treatment efficacy while minimizing risks, it is critical to identify reliable predictors of positive response to varenicline in smokers with schizophrenia. OBJECTIVES: Negative symptoms of schizophrenia are related to dysfunctions in the brain reward system, are associated with nicotine dependence, and may be improved by nicotine or nicotinic receptor agonists, suggesting that smoking cessation may be especially difficult for patients with substantial negative symptoms. The purpose of the study was to evaluate negative symptoms as predictors of response to varenicline. METHODS: Patients with schizophrenia (N = 53) completed a 12-week smoking cessation trial combining varenicline with cognitive behavioral therapy. Negative symptoms were assessed via the Scale for the Assessment of Negative Symptoms (Andreasen 1983). Outcomes included smoking abstinence as assessed by self-report and expired carbon monoxide. Change in performance on a probabilistic reward task was used as an index of change in reward sensitivity during treatment. RESULTS: At week 12, 32 participants met criteria for 14-day point-prevalence abstinence. Patients with lower baseline symptoms of affective flattening (more typical affect) were more likely to achieve smoking abstinence and demonstrated larger increases in reward sensitivity during treatment. CONCLUSIONS: These data suggest that affective flattening symptoms in smokers with schizophrenia may predict response to varenicline.
RATIONALE: Smoking rates are up to five times higher in people with schizophrenia than in the general population, placing these individuals at high risk for smoking-related health problems. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, is a promising aid for smoking cessation in this population. To maximize treatment efficacy while minimizing risks, it is critical to identify reliable predictors of positive response to varenicline in smokers with schizophrenia. OBJECTIVES: Negative symptoms of schizophrenia are related to dysfunctions in the brain reward system, are associated with nicotine dependence, and may be improved by nicotine or nicotinic receptor agonists, suggesting that smoking cessation may be especially difficult for patients with substantial negative symptoms. The purpose of the study was to evaluate negative symptoms as predictors of response to varenicline. METHODS:Patients with schizophrenia (N = 53) completed a 12-week smoking cessation trial combining varenicline with cognitive behavioral therapy. Negative symptoms were assessed via the Scale for the Assessment of Negative Symptoms (Andreasen 1983). Outcomes included smoking abstinence as assessed by self-report and expired carbon monoxide. Change in performance on a probabilistic reward task was used as an index of change in reward sensitivity during treatment. RESULTS: At week 12, 32 participants met criteria for 14-day point-prevalence abstinence. Patients with lower baseline symptoms of affective flattening (more typical affect) were more likely to achieve smoking abstinence and demonstrated larger increases in reward sensitivity during treatment. CONCLUSIONS: These data suggest that affective flattening symptoms in smokers with schizophrenia may predict response to varenicline.
Authors: Georg Juckel; Florian Schlagenhauf; Michael Koslowski; Torsten Wüstenberg; Arno Villringer; Brian Knutson; Jana Wrase; Andreas Heinz Journal: Neuroimage Date: 2005-09-01 Impact factor: 6.556
Authors: David J Scott; Edward F Domino; Mary M Heitzeg; Robert A Koeppe; Lisong Ni; Sally Guthrie; Jon-Kar Zubieta Journal: Neuropsychopharmacology Date: 2006-11-08 Impact factor: 7.853
Authors: Lauren V Moran; Luke E Stoeckel; Kristina Wang; Carolyn E Caine; Rosemond Villafuerte; Vanessa Calderon; Justin T Baker; Dost Ongur; Amy C Janes; A Eden Evins; Diego A Pizzagalli Journal: Psychopharmacology (Berl) Date: 2017-11-27 Impact factor: 4.530
Authors: Jillian J Weeks; Laura E Rupprecht; Anthony A Grace; Eric C Donny; Alan F Sved Journal: Nicotine Tob Res Date: 2020-02-06 Impact factor: 4.244
Authors: Randi M Schuster; Corinne Cather; Gladys N Pachas; Haiyue Zhang; Kristina M Cieslak; Susanne S Hoeppner; David Schoenfeld; A Eden Evins Journal: Addict Behav Date: 2017-02-24 Impact factor: 3.913
Authors: Alexis E Whitton; Alan I Green; Diego A Pizzagalli; Robert M Roth; Jill M Williams; Mary F Brunette Journal: Schizophr Bull Date: 2019-10-24 Impact factor: 9.306
Authors: Gladys N Pachas; Corinne Cather; Sarah A Pratt; Bettina Hoeppner; Johanna Nino; Sara V Carlini; Eric D Achtyes; Harry Lando; Kim T Mueser; Nancy A Rigotti; Donald C Goff; A Eden Evins Journal: J Dual Diagn Date: 2012-05-11